|
|
 |
|
Viewing report
|
|
|
|
Amylin Pharmaceuticals, Inc.: Company Profile and SWOT Analysis
iCD Research, Sep 2011, Pages: 43
Synopsis
ICD Research's 'Amylin Pharmaceuticals, Inc.: Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, competitor benchmarking data, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
Summary
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's 'Amylin Pharmaceuticals, Inc.: Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about Amylin Pharmaceuticals, Inc. for business intelligence requirements
- Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
- Provides analysis on financial ratios along with a competitor benchmarking section
- The profile also contains information on business operations, company history, major products and services, prospects, key competitors, key employees, locations and subsidiaries
Reasons To Buy
- Quickly enhance your understanding of the company
- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
- Increase business/sales activities by understanding your competitors’ businesses better
- Recognize potential partnerships and suppliers
- Obtain yearly profitability figures
Key Highlights
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company that specializes in the development and marketing of innovative medicines for the treatment of diabetes, obesity and other diseases. It markets two medicines, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection to treat diabetes. Through a network of wholesale distributors, Amylin sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers and other third-party players. Amylin also entered into strategic agreement and collaboration with various companies such as Alkermes, Inc., Biocon Limited, Eli Lilly and Company, Psylin Neurosciences, Inc., and Takeda Pharmaceutical Company Limited develop novel treatments for the patients. The company owns and maintains commercial manufacturing facility in Ohio, the US. Amylin is headquartered in San Diego, California, the US.
|
|
|
|
